XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

April 25, 2024

https://www.globenewswire.com/news-release/2024/04/25/2869527/7281/en/XOMA-Earns-9-Million-Milestone-as-FDA-Grants-Accelerated-Approval-to-Day-One-s-OJEMDATM-tovorafenib-for-Relapsed-or-Refractory-BRAF-altered-Pediatric-Low-Grade-Glioma-pLGG.html

XOMA is entitled to a mid-single digit royalty on global OJEMDA™ sales

First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.